Cell therapy CER-1236 put on FDA fast track as AML treatment
The U.S. Food and Drug Administration (FDA) has granted fast track designation to CER-1236, an experimental cell therapy that Cero Therapeutics is developing to…
Marisa Wexler, MS, senior science writer—
Articles by Marisa Wexler
Chemical in cigarette smoke drives pancreatic cancer: Study
A chemical in cigarette smoke can increase the odds of developing pancreatic cancer by changing the immune system’s activity. That’s according to a new…
New strategy targets the ‘mesh’ around tumors to stop glioblastoma
Researchers may have found a way to halt the spread of aggressive brain tumors by targeting the environment around the cancer cells. A new study…
Groups unite to raise gynecologic cancer awareness in September
September is Gynecologic Cancer Awareness Month, and advocacy organizations are hosting events, sharing information on social media, and raising funds to advance research.
Glioblastoma treatment combo shows promise in pilot study
A combination therapy for glioblastoma showed encouraging early results, with all five patients treated in a pilot study responding to it. Based on the data,…
Modeyso becomes 1st FDA-approved treatment for rare glioma
Jazz Pharmaceuticals said the U.S. Food and Drug Administration (FDA) granted accelerated approval to the weekly oral therapy dordaviprone, to be marketed under the brand…
Blood cancer therapy SGR-2921 discontinued after patient deaths
Biotech company Schrödinger said it’s discontinuing the development of SGR-2921, an experimental therapy for certain types of blood cancer, following the deaths of…
Patients needed for trial of CUE-102 for hard-to-treat glioblastoma
Enrollment is now open in a U.S. clinical trial testing the immune-modulating therapy CUE-102 in people with recurrent glioblastoma, an aggressive form of glioma…
Ovarian cancer patients wanted for Phase 3 trial of virus therapy
A Phase 3 clinical trial testing the experimental cancer-killing virus Olvi-Vec in people with hard-to-treat ovarian cancer is recruiting participants. Top-line results from the ongoing…
Sanofi multiple myeloma treatment gets FDA orphan drug status
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an investigational therapy being developed by Sanofi for people with…
